Neusignal Therapeutics

Neusignal Therapeutics is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for neurological and neurodegenerative disorders. The company utilizes the Similarity Ensemble Approach (SEA), a proprietary computational platform developed at the University of California, San Francisco (UCSF), to predict drug-target interactions and identify novel ligands for orphan receptors. Neusignal's research primarily targets G protein-coupled receptors (GPCRs) to address high unmet needs in conditions such as Alzheimer's disease, Parkinson's disease, and chronic pain. By integrating advanced chemoinformatics with biological validation, the company aims to streamline the drug discovery process for complex central nervous system diseases.